Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Clinical Trial ID NCT02859142

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02859142

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 10.31
2 Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005 6.13
3 Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004 5.94
4 Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014 1.11
5 Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology (Berl) 2010 0.89
Next 100